检索结果-南通市图书馆

Reese-Ellsworth综合征Vb组视网膜母细胞瘤患者接受初始体外放射线治疗后的结局

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（眼科学分册） 2005年第2期1卷 18-19页

作者： Abramson d.H. Beaverson K.L. Chang S.T. 张磊 department of Ophthalmology New York Presbyterian Hospital Weill Med. Coll. of Cornell Un iv. 70 E 66th St NewYork NY10021United States Dr.

Objective: To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth groupVb ret inoblastoma. Methods: Retrospective case series (from January 1, 1979, to Februa ry 28, 2002). The Kaplan-Meier method was used to analyze survival (ocular and patient) and incidence (second cancer)-data. Results: Two hundred forty-three patients with 1 or more Reese-Ellsworth group Vb eyes were identified. Of 284 g roup Vb eyes, 63 (22.2%) initially received EBT, vs 172 (60.6%) that were init ially enucleated. Of the 63 radiated group Vb eyes, 31 (49.2%) had no further t umor growth, 26 (41.3%) developed a recurrence, and 8 (12.7%) developed a new tumor. Of the 63 radiated group Vb eyes, 33 (52.4%) developed ocular complicati ons. The ocular survival rate of radiated group Vb eyes was 81.4%at 1 year and 53.4%at 10 years. Twenty-eight radiated group Vb eyes survived to the last fol low-up with visual acuity information. Thirteen patients developed second cance rs, 11 in the field of radiation. The probability of developing a second cancer following initial EBT for group Vb disease in patients with bilateral disease wa s 29.7%by 10 years after diagnosis. Survival from second cancers in patients wi th bilateral disease initially receiving EBT for group Vb disease was 93.6%at 5 years and 52.6%at 181/4 years. No patient with unilateral disease developed a second cancer. deaths due to metastatic retinoblastoma were uncommon. Conclusion s: To our knowledge, this is the first study focusing exclusively on group Vb ey es treated initially with EBT, most of which were salvaged with vision. Outcome data provided herein are clinically relevant when choosing treatment options for advanced intraocular retinoblastoma.

关键词：视网膜母细胞瘤 Vb 初始体眼球摘除术接受体病例研究眼部并发症最后一次日至

平坦部玻璃体切割治疗眼部Behcet并发症

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（眼科学分册） 2005年第11期1卷 35-36页

作者： Sullu Y. Alotaiby H. Beden U. Erkan d. 邢咏新 department of Ophthalmology Faculty of Medicine Ondokuz Mayis University 55139 Samsun Turkey

BACKGROUNd ANd OBJECTIVES: To evaluate the outcomes of vitreoretinal surgery f or the ocular complications of Behet’s disease. PATIENTS ANd METHOdS: This re trospective study included 20 eyes of 15 patients with Behet’s disease (9 men , 6 women; mean age at surgery, 31.0±1.8 years; range, 21-44 years) who had un dergone vitreoretinal surgery for Behet’s disease at Ondokuz Mayis University , Faculty of Medicine, department of Ophthalmology, Samsun, Turkey, between Janu ary 2000 and September 2003. Postoperative visual acuity outcome, course of uvei tis, and complications were evaluated in all patients. RESULTS: Indications for surgery were vitreous opacities in 10 eyes (50%), cystoid macular edema in 5 ey es (25%), epiretinal membrane in 3 eyes (15%)-, and vitreous hemorrhage in 2 eyes (10%). At the last postoperative follow-up, visual acuity had increased 2 Snellen lines or more in 10 (50%) of 20 eyes. Cystoid macular edema completely improved in 3 (60%) of 5 eyes after vitrectomy. Uveitis attacks significantly decreased during follow-up (P=.015). Immunosuppressive treatment was stopped in 11 (73%) of 15 patients. Retinal detachment and phthisis were not observed in any eye. CONCLUSION: Vitreoretinal surgery may be useful in the treatment of pos terior segment complications of Behet’s disease.

关键词：玻璃体切割 Behcet 玻璃体切除术视网膜脱离术后视力葡萄膜炎玻璃体出血黄斑囊样水肿视网膜前膜玻璃体混浊

Intravenous immune globulin suppresses angiogenesis in mice and humans

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2016年第1期1卷 141-148页

作者： Reo Yasuma Valeria Cicatiello Takeshi Mizutani Laura Tudisco Younghee Kim Valeria Tarallo Sasha Bogdanovich Yoshio Hirano Nagaraj Kerur Shengjian Li Tetsuhiro Yasuma Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Balamurali K Ambati Sevim Barbasso Helmers Ingrid E Lundberg Ondrej Viklicky Jeanette HW Leusen J Sjef Verbeek brad.ey d Gelfand Ana Bastos-Carvalho Sandro de Falco Jayakrishna Ambati department of Ophthalmology and Visual Sciences University of KentuckyLexingtonKYUSA department of Ophthalmology Nagoya University Graduate School of MedicineNagoyaJapan Angiogenesis Lab Institute of Genetics and Biophysics—CNRNaplesItaly Bio-Ker MultiMedica GroupNaplesItaly department of Physiology University of KentuckyLexingtonKYUSA department of Advanced Biomedical Sciences University of Naples‘Federico II’NaplesItaly CEINGE—Biotecnologie Avanzate s.c.ar.l.NaplesItaly department of Ophthalmology and Visual Sciences Moran Eye CenterUniversity of Utah School of MedicineSalt Lake CityUTUSA department of Ophthalmology Veterans Affairs Salt Lake City Healthcare SystemSalt Lake CityUTUSA Rheumatology Unit Department of MedicineKarolinska InstitutetKarolinska University HospitalStockholmSweden department of Nephrology Institute for Clinical and Experimental MedicinePrague 4Czech Republic Immunotherapy Laboratory Laboratory for Translational ImmunologyUniversity Medical Center UtrechtUtrechtThe Netherlands department of Human Genetics Leiden University Medical CenterLeidenThe Netherlands department of Biomedical Engineering University of KentuckyLexingtonKYUSA department of Microbiology Immunologyand Molecular GeneticsUniversity of KentuckyLexingtonKYUSA IRCCS MultiMedica MilanoItaly

Human intravenous immune globulin(IVIg),a purified IgG fraction composed of~60%IgG1 and obtained from the pooled plasma of thousands of donors,is clinically used for a wide range of *** biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG(IgG)Fc ***,we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcγRI,a high-affinity receptor for *** we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases,namely,neovascular age-related macular degeneration,corneal neovascularization,colorectal cancer,fibrosarcoma and peripheral arterial ischemic *** was mediated by the Fc region of IVIg,required FcγRI and had similar potency in transgenic mice expressing human Fcγ***,IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel *** data place IVIg,an agent approved by the US Food and drug Administration,as a novel angioinhibitory drug in doses that are currently administered in the clinical *** addition,they raise the possibility of an unintended effect of IVIg on blood vessels.

关键词： doses inhibited degeneration

原发性视网膜脱离(急性玻璃体后脱离所致)患者治疗后发生继发性视网膜脱离的发病率和临床表现

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（眼科学分册） 2005年第1期1卷 15-15页

作者：赵炜 Sharma M.C Regillo C.d Shuler M.F Retina Serv.of the Wills ey e Hosp. Thomas Jefferson UniversityPhiladelphiaPAUnited States.Dr.

Purpose To determine the incidence o f subsequent retinal tears(SRT)in patients who were previously treated for acute posterior vitreous detachmen t(PVd)-related retinal *** Retrospective chart r *** A ret-rospective chart review of 155eyes o f 137consecutive patients treated for acute PVd-rela ted retinal tears was *** during a median f ollow-up of 13months(range 3to 157months)after treatment,SRT developed in 19(12.2%)of 155treated *** of the SRT occurred during the first 6mo nths(12of 19eyes)after initial *** t vetinal tears de-veloped within the first 12months in15of 19treated eyes,however only six of 15of these eyes we re *** those patients who developed SRT aft er 12months,all had new visual *** Patients who present with acute PVd-related retinal tears are at a low but sig-nificant risk for developing SRT.A s ignificant number of patients treated for PVd-associate d retinal tears present within 1year with SRT without sympto ms.

关键词：玻璃体后脱离视网膜脱离视觉症状眼部症状性图

在线全文

学校读者我要写书评

暂无评论

鸟枪弹样视网膜病变:眼部并发症及视觉损害

世界核心医学期刊文摘（眼科学分册） 2005年第12期1卷 8-8页

作者： Thorne J.E Jabs d.A Peters G.B 陈立军 Wilmer eye Institute 550 North Broadway Baltimore MD 21205 United States Dr.

PURPOSE: To describe the incidence of vision loss and of ocular complications attributable to birdshot retinochoroido-pathy and to describe the association between therapy and the incidence thereof. dESIGN: Retrospective cohort study. METHOdS: setting: Single-center, academic practice. study population: Forty patients with birdshot retinochoroidopathy were evaluated from January 1984 through March 2004. observation procedure: demographic and clinical information on patients diagnosed with birdshot retinochoroidopathy was collected. main outcome measures: Visual acuity and visual field loss; ocular complications including cystoid macular edema (CME). RESULTS: In affected eyes, the frequencies of vision loss to 20/50 or worse and to 20/200 or worse and of CME at presentation were 33% , 13% , and 20% , respectively. Patients who presented with a duration of disease of ≥ 30 months had higher frequencies of visual impairment to 20/50 or worse (68% vs 32% ; P=.004) and to 20/200 or worse (32% vs 9% ; P=.01), and had a higher frequency of CME (38% vs 14% ; P=.02) than patients who presented with a duration of disease dence rates on follow-up for vision loss to 20/50 or worse and to 20/200 or worse were 13% and 4% per eye-year (ey), respectively. The incidence of CME was 10% /ey. Use of immunosuppressive drug therapy was associated with a reduced risk of developing CME (relative risk=0.17; 95% confidence interval: 0.05, 0.64; P=.009). CONCLUSIONS: Birdshot retinochoroidopathy is a progressive disease with the potential for visual impairment. Patients who present at a later date after the onset of disease were more likely to have vision impairment and CME. Use of long-term immunosuppressive therapy may reduce the risk of CME.

关键词：视网膜病变眼部并发症视力损害囊样黄斑水肿视野损害患眼视力临床信息研究人群视功能回顾性队列研究

Human IgG1 antibodies suppress angiogenesis in a target-independent manner

在线全文

学校读者我要写书评

暂无评论

Signal Transduction and Targeted Therapy 2016年第1期1卷 158-171页

作者： Sasha Bogdanovich Younghee Kim Takeshi Mizutani Reo Yasuma Laura Tudisco Valeria Cicatiello Ana Bastos-Carvalho Nagaraj Kerur Yoshio Hirano Judit Z Baffi Valeria Tarallo Shengjian Li Tetsuhiro Yasuma Parthasarathy Arpitha Benjamin J Fowler Charles B Wright Ivana Apicella Adelaide Greco Arturo Brunetti Menotti Ruvo Annamaria Sandomenico Miho Nozaki Ryo Ijima Hiroki Kaneko Yuichiro Ogura Hiroko Terasaki Balamurali K Ambati Jeanette HW Leusen Wallace Y Langdon Michael R Clark Kathryn L Armour Pierre Bruhns J Sjef Verbeek brad.ey d Gelfand Sandro de Falco Jayakrishna Ambati department of Ophthalmology and Visual Sciences University of KentuckyLexingtonKYUSA department of Ophthalmology and Visual Science Nagoya City University Graduate School of Medical SciencesNagoyaJapan department of Ophthalmology Nagoya University Graduate School of MedicineNagoyaJapan Angiogenesis Lab Institute of Genetics and Biophysics—CNRNaplesItaly Bio-Ker MultiMedica GroupNaplesItaly department of Advanced Biomedical Sciences University of Naples‘Federico II’NaplesItaly CEINGE—Biotecnologie Avanzate s.c.a.r.l.NaplesItaly Istituto di Biostrutture e Bioimmagini CNRNaplesItaly department of Ophthalmology and Visual Sciences Moran Eye CenterUniversity of Utah School of MedicineSalt Lake CityUTUSA department of Ophthalmology Veterans Affairs Salt Lake City Healthcare SystemSalt Lake CityUTUSA Immunotherapy Laboratory Laboratory for Translational ImmunologyUniversity Medical Center UtrechtUtrechtThe Netherlands School of Pathology and Laboratory Medicine University of Western AustraliaCrawleyWAAustralia division of Immunology Department of PathologyUniversity of CambridgeCambridgeUK department of Immunology Unit of Antibodies in Therapy and PathologyInstitut PasteurParisFrance Institut National de la Santéet de la Recherche Médicale(INSERM)U1222 ParisFrance department of Human Genetics Leiden University Medical CenterLeidenThe Netherlands department of Biomedical Engineering University of KentuckyLexingtonKYUSA department of Microbiology Immunologyand Molecular GeneticsUniversity of KentuckyLexingtonKYUSA IRCCS MultiMedica MilanoItaly department of Physiology University of KentuckyLexingtonKYUSA.

Aberrant angiogenesis is implicated in diseases affecting nearly 10%of the world’s *** most widely used antiangiogenic drug is bevacizumab,a humanized IgG1 monoclonal antibody that targets human *** bevacizumab does not recognize mouse Vegfa,it inhibits angiogenesis in *** we show bevacizumab suppressed angiogenesis in three mouse models not via Vegfa blockade but rather Fc-mediated signaling through FcγRI(Cd64)and c-Cbl,impairing macrophage *** approved humanized or human IgG1 antibodies without mouse targets(adalimumab,alemtuzumab,ofatumumab,omalizumab,palivizumab and tocilizumab),mouse IgG2a,and overexpression of human IgG1-Fc or mouse IgG2a-Fc,also inhibited angiogenesis in wild-type and FcγR humanized *** anti-angiogenic effect was abolished by Fcgr1 ablation or knockdown,Fc cleavage,IgG-Fc inhibition,disruption of Fc-FcγR interaction,or elimination of FcRγ-initated ***,bevacizumab’s Fc region potentiated its anti-angiogenic activity in humanized VEGFA ***,mice deficient in FcγRI exhibited increased developmental and pathological *** findings reveal an unexpected anti-angiogenic function for FcγRI and a potentially concerning off-target effect of hIgG1 therapies.

关键词： Cd64 angiogenesis antibodies

Nature：大规模研究揭示生命所必需的基因

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

现代生物医学进展 2016年第31期16卷 I0002-I0003页

作者： dickinson, Mary E. Flenniken, Ann M. Ji, Xiao Teboul, Lydia Wong, Michael d. White, Jacqueline K. Meehan, Terrence F. Weninger, Wolfgang J. Westerberg, Henrik Adissu, Hibret Baker, Candice N. Bower, Lynette Brown, James M. Caddle, L. Brianna Chiani, Francesco Clary, dave Cleak, James daly, Mark J. denegre, James M. doe, Brendan dolan, Mary E. Edie, Sarah M. Fuchs, Helmut Gailus-durner, Valerie Galli, Antonella Gambadoro, Alessia Gallegos, Juan Guo, Shiying Horner, Neil R. Hsu, Chih-Wei Johnson, Sara J. Kalaga, Sowmya Keith, Lance C. Lanoue, Louise Lawson, Thomas N. Lek, Monkol Mark, Manuel Arschall, Susan M. Mason, Jeremy McElwee, Melissa L. Newbigging, Susan Nutter, Lauryl M. J. Peterson, Kevin A. Ramirez-Solis, Ramiro Rowland, douglas J. Ryder, Edward Samocha, Kaitlin E. Seavitt, John R. Selloum, Mohammed Szoke-Kovacs, Zsombor Tamura, Masaru Trainor, Amanda G. Tudose, Ilinca Wakana, Shigeharu Warren, Jonathan Wendling, Olivia West, david B. Wong, Leeyean Yoshiki, Atsushi MacArthur, daniel G. Tocchini-Valentini, Glauco P. Gao, Xiang Flicek, Paul brad.ey, Allan Skarnes, William C. Justice, Monica J. Parkinson, Helen E. Moore, Mark Wells, Sara Braun, Robert E. Svenson, Karen L. de Angelis, Martin Hrabe Herault, Yann Mohun, Tim Mallon, Ann-Marie Henkelman, R. Mark Brown, Steve d. M. Adams, david J. Lloyd, K. C. Kent McKerlie, Colin Beaudet, Arthur L. Bucan, Maja Murray, Stephen A. dept Mol Physiol & Biophys Houston TX 77030 USA Toronto Ctr Phenogen Toronto ON M5T 3H7 Canada Mt Sinai Hosp Toronto ON M5G 1X5 Canada Univ Penn Perelman Sch Med Genom & Computat Biol Program Philadelphia PA 19104 USA Med Res Council Harwell Mammalian Genet Unit Harwell OX11 0RD Oxon England Mary Lyon Ctr Harwell OX11 0RD Oxon England Hosp Sick Children Mouse Imaging Ctr Toronto ON M5T 3H7 Canada Wellcome Trust Sanger Inst Wellcome Trust Genome Campus Cambridge CB10 1SA England European Bioinformat Inst European Mol Biol Lab Wellcome Trust Genome Campus Cambridge CB10 1SD England Med Univ Vienna Ctr Anat & Cell Biol A-1090 Vienna Austria Hosp Sick Children 555 Univ Ave Toronto ON M5G 1X8 Canada Jackson Lab 600 Main St Bar Harbor ME 04609 USA Univ Calif davis Mouse Biol Program Davis CA 95618 USA Italian Natl Res Council CNR Inst Cell Biol & Neurobiol Monterotondo Mouse Clin I-00015 Monterotondo Italy Massachusetts Gen Hosp Analyt & Translat Genet Unit Boston MA 02114 USA Broad Inst MIT & Harvard Program Med & Populat Genet Cambridge MA 02142 USA German Res Ctr Environm Hlth Helmholtz Zentrum Munchen Inst Expt Genet D-85764 Neuherberg Germany German Mouse Clin D-85764 Neuherberg Germany Baylor Coll Med Dept Mol & Human Genet Houston TX 77030 USA Nanjing Univ Nanjing Biomed Res Inst Collaborat Innovat Ctr Genet & Dev SKL Pharmaceut Biotechnol & Model Anim Res Ctr Nanjing 210061 Jiangsu Peoples R China Univ Strasbourg ICS Infrastruct Natl PHENOMIN F-67404 Illkirch Graffenstaden France Univ Strasbourg INSERM CNRS IGBMC F-67404 Illkirch Graffenstaden France RIKEN BioResource Ctr Tsukuba Ibaraki 3050074 Japan Childrens Hosp Oakland Res Inst Oakland CA 94609 USA IMPC San Anselmo CA 94960 USA Tech Univ Munich Sch Life Sci Weihenstephan Chair Expt Genet D-81675 Freising Weihenstephan Germany German Ctr diabet Res dZd D-85764 Neuherberg Germany Francis Crick Inst Mill Hill Lab Mill Hill London NW1 1AT England Univ Penn Perlman

在哺乳动物基因组中。大约三分之一的基因是生命所必需的。在一项新的研究中，来自美国贝勒医学院等多个机构的研究人员描述了这些基因的大规模发现。以及它将如何影响对哺乳动物发育和人类疾病的理解。相关研究结果在线发表在Nature期... 详细信息

在哺乳动物基因组中。大约三分之一的基因是生命所必需的。在一项新的研究中，来自美国贝勒医学院等多个机构的研究人员描述了这些基因的大规模发现。以及它将如何影响对哺乳动物发育和人类疾病的理解。相关研究结果在线发表在Nature期刊上，论文标题为“High—throughput discovery of novel developmental phenotypes”。

关键词：动物基因组生命哺乳动物研究人员人类疾病医学院